Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06138067 | Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients | recruiting | N/A | 90 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06470750 | Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP) | completed | — | 75 | Mayo ClinicOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 156 | Context Therapeutics Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06837896 | Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer | completed | Phase 3 | 111 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | Phase 2 | 85 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07005154 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | recruiting | Phase 2 | 218 | Astellas Pharma Global Development, Inc.INDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07285694 | AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | active not recruiting | Phase 1 / Phase 2 | 190 | Arsenal Biosciences, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07287150 | A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer(InavoPC) | recruiting | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07545811 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 43 | Janux TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07578519 | Radiation Treatment of the Prostate That is Specially Adjusted for Each Person | recruiting | Phase 2 | 50 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07674225 | Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer(DESTINATION 2) | active not recruiting | N/A | 24 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07685249 | Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment(RESTORE-PC) | not yet recruiting | N/A | 30 | Duke UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07723248 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)(Himalayas-1) | recruiting | Phase 3 | 600 | ORIC PharmaceuticalsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801664 | Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer | recruiting | Phase 2 | 90 | NYU Langone HealthOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT00756665 | Prostate Active Surveillance Study(PASS) | recruiting | — | 3,000 | University of WashingtonOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT03181867 | 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | active not recruiting | Phase 2 | 360 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03762759 | Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes | active not recruiting | Phase 2 | 140 | Emory UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04962919 | Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.(LACOG 1818) | completed | — | 584 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04997018 | A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer | active not recruiting | Phase 2 | 91 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05700903 | Contributions to Hypertension With Androgen Deprivation Therapy(ARCH) | terminated | Phase 4 | 10 | University of Colorado, DenverOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial(PREDICT) | recruiting | Phase 2 | 474 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06931340 | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | recruiting | Phase 3 | 1,260 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07200830 | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial | recruiting | Phase 3 | 1,524 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07609225 | Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy | not yet recruiting | Early Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07796490 | Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07800390 | proState Cancer Health Education to pRomote Early sreENing Uptake (SCREEN): A Pilot Randomised Control Trial(SCREEN) | not yet recruiting | N/A | 74 | Teesside UniversityOTHER | 0 | Sep 2, 2026 | clinicaltrials |
| NCT01923506 | Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery | active not recruiting | Phase 1 | 26 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02766686 | Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons(ProtoChoiceP) | completed | N/A | 180 | Technische Universität DresdenOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05647564 | PET/CT Characterization of Treatment Resistance | recruiting | N/A | 25 | University of Wisconsin, MadisonOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05710380 | MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy | recruiting | N/A | 180 | University of ChicagoOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07162194 | MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial | recruiting | N/A | 130 | University of Southern CaliforniaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07798778 | Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer(SRT-017-001) | recruiting | Early Phase 1 | 18 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT00761124 | Informed Decision-Making Regarding Prostate Specific Antigen (PSA) Screening in 50-70 Year Old Latino Men(PSA) | completed | N/A | 1,006 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02305654 | International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)(InPACT) | active not recruiting | Phase 3 | 200 | Institute of Cancer Research, United KingdomOTHER | 2 | Aug 31, 2026 | clinicaltrials |
| NCT04925063 | The Effect of Metformin in Patients With Newly Diagnosed mHSPC | active not recruiting | Phase 2 | 266 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05726292 | A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | recruiting | Phase 2 | 90 | University of ChicagoOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05942001 | Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06600698 | Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA | recruiting | Phase 1 / Phase 2 | 45 | Milton S. Hershey Medical CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06654336 | Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)(RATIONAL) | recruiting | Phase 2 | 162 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06865547 | ProA Study: ProActive Management Model in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated by Apalutamide(ProA) | active not recruiting | — | 94 | Yonghong LiOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07111507 | A Study of Tarlatamab for People With Prostate Cancer | recruiting | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07466498 | Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial | not yet recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07790003 | Dietary Fibre Supplementation to Delay Disease Progression in Early Prostate Cancer(DEFINITE) | completed | — | 10 | University of AberdeenOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07795268 | Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | not yet recruiting | Phase 3 | 600 | Norroy Bioscience Co., LTDINDUSTRY | 0 | Aug 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 3, 2026source: clinicaltrials